Sort
23,748 grants matching “melanoma”
Non-Melanoma Skin Cancer in New Hampshire
$732,130Margaret Rita Karagas · Dartmouth College · R01 · FY2015 · CA
Investigating Regulatory Networks that Control Cell Proliferation and Apoptosis
$732,104Kurt Kohn · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA
Identifying modifiable factors that reduce the burden of late stage melanoma in Hispanics
$732,039Myles G Cockburn · University Of Southern California · R01 · FY2025 · CA
Interrogating unique DC adaptations to tissue to promote barrier immunity and tolerance
$732,031Niroshana Anandasabapathy · Weill Medical Coll Of Cornell Univ · R01 · FY2023 · AR
Development of BRAF Dimer Inhibitors to Treat Drug Resistant Melanoma
$731,727Ronen Marmorstein · University Of Pennsylvania · R01 · FY2020 · CA
Modifying Young Adult Skin Cancer Risk and Protective Behaviors (UV4.me2): A Hybrid Type 2 Dissemination/Effectiveness Trial
$731,671Carolyn J. Heckman · Research Inst Of Fox Chase Can Ctr · R01 · FY2017 · CA
(PQ5) Mitochondrial Heterogeneity in Melanoma Tumor and Immune Responses
$731,547Gerald S Shadel · Salk Institute For Biological Studies · R01 · FY2020 · CA
Role of Neurotrophins in the Development of the Mammalian Nervous System
$731,359Lino Tessarollo · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA
DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targets for Anticancer Drugs
$731,268Yves Pommier · Basic Sciences · Z01 · FY2007 · CA
Building the foundations of commensal vaccines
$730,870Michael Andrew Fischbach · Stanford University · R01 · FY2025 · AI
A novel preclinical model of spontaneous metastasis
$730,435Glenn T. Merlino · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA
Leveraging Radiation-Induced Senescence and PTPN2 Inhibition to Enhance Immune-Mediated Tumor Control in Rectal Cancer
$730,398Paul Bernard Romesser · Sloan-Kettering Inst Can Research · R37 · FY2025 · CA
Clinical production of viral vectors for cancer gene therapy
$730,187Rachel Beyer · Division Of Basic Sciences - Nci · ZIC · FY2019 · CA
Non-Melanoma Skin Cancer in New Hampshire
$730,106Margaret Rita Karagas · Dartmouth College · R01 · FY2014 · CA
Small molecule enhancers of tumor immunity targeting the LPA5 GPCR
$729,283Gabor J Tigyi · University Of Tennessee Health Sci Ctr · R01 · FY2025 · CA
Noninvasive Contrast Enhanced Early Detection of Melanoma Liver Metastasis
$728,995Jenny J Yang · Inlighta Biosciences, Llc · R42 · FY2018 · CA
Overcoming adaptive feedback resistance to KRAS inhibition in colorectal cancer
$728,990Ryan Bruce Corcoran · Massachusetts General Hospital · R01 · FY2022 · CA
Ms. LILAC: Muscle Mass in the Life and Longevity After Cancer (LILAC) Study
$728,401Hailey Rose Banack · State University Of New York At Buffalo · R37 · FY2022 · CA
Genetics of Complex Diseases and Health Disparities
$728,353Cheryl Winkler · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
MYELOID-DERIVED SUPPRESSOR CELLS IN CHECKPOINT PROTEIN INHIBITION FOR MELANOMA
$727,540The Wistar Institute Of Anatomy And Biology · · FY2016 · Department of the Army
MYELOID-DERIVED SUPPRESSOR CELLS IN CHECKPOINT PROTEIN INHIBITION FOR MELANOMA
$727,275The Wistar Institute Of Anatomy And Biology · · FY2016 · Department of the Army
Harnessing double stranded-RNA (dsRNA)-response and anti-tumor effect in PRC2-inactivated cancer
$727,224Ping Chi · Sloan-Kettering Inst Can Research · R01 · FY2025 · CA
IMMUNOTHERAPEUTIC TARGETING OF SLC39A9 IN CDKN2A-LOW MELANOMA
$726,989University Of Pittsburgh - Of The Commonwealth System Of Higher Education · · FY2025 · Defense Health Agency
Mechanisms driving acute and chronic kidney function decline after immune checkpoint inhibitor therapy for cancer
$726,788Meghan E. Sise · Massachusetts General Hospital · R01 · FY2022 · DK
Mechanisms driving acute and chronic kidney function decline after immune checkpoint inhibitor therapy for cancer
$726,628Meghan E. Sise · Massachusetts General Hospital · R01 · FY2023 · DK